The Role of Pulmonary Surfactants in the Treatment of Acute Respiratory Distress Syndrome in COVID-19
Lung alveolar type-II (AT-II) cells produce pulmonary surfactant (PS), consisting of proteins and lipids. The lipids in PS are primarily responsible for reducing the air-fluid surface tension inside the alveoli of the lungs and to prevent atelectasis. The proteins are of two types: hydrophilic and h...
Saved in:
Main Authors: | Shengguang Wang (Author), Zhen Li (Author), Xinyu Wang (Author), Shiming Zhang (Author), Peng Gao (Author), Zuorong Shi (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Surfactant therapy for acute respiratory distress in infants
by: Corrado Moretti, et al.
Published: (2014) -
Treatment of acute respiratory distress syndrome in secondary surfactant deficiency in neonates
by: Heru Samudro, et al.
Published: (2016) -
Surfactant Therapy for Respiratory Distress Syndrome in High- and Ultra-High-Altitude Settings
by: Xudong Duan, et al.
Published: (2022) -
Aerosolized Surfactant for Preterm Infants with Respiratory Distress Syndrome
by: Mandy Brasher, et al.
Published: (2021) -
FiO2 Before Surfactant, but Not Time to Surfactant, Affects Outcomes in Infants With Respiratory Distress Syndrome
by: Piotr Kruczek, et al.
Published: (2021)